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Chapter 1 
Introduction and scope of the thesis 
Upper respiratory tract infections (URTl's) are of particular importance to 
ultradistance runners. Even a minor illness can limit training and may impair sports 
performance. Many athletes believe that regular strenuous exercise improves their 
resistance to infection and there are anecdotal reports that athletes have fewer 
upper respiratory tract infections (Brenner et al, 1994). 
However, in runners it has been found that the risk of developing symptoms of 
upper respiratory tract infections within two weeks after an ultramarathon (56km) 
event is double compared to sedentary controls (Peters et al, 1983). It also been 
shown that the risk of an "infectious episode" was fivefold higher in runners one 
week after a marathon race than in runners who trained but did not compete in the 
race (Nieman et al, 1990). There also seems to be a significant association between 
the development of upper respiratory tract symptoms and high weekly training 
distance (Heath et al, 1991; Nieman et al, 1990; Peters et al, 1983; Peters et al, 
1993). Moreover, faster runners reported more symptoms, indicating a possible 
relationship between exercise intensity and the development of upper respiratory 
tract symptoms (Brenner et al, 1994; Peters et al, 1990). 
The precise mechanism by which high intensity, prolonged exercise increases the 
susceptibility to symptoms of upper respiratory tract infections remains obscure. 
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Studies investigating the relationship between exercise and immune function have 
demonstrated a wide variety of changes in immune function in response to both 
acute bouts of exercise as well as prolonged regular exercise training (Berk et al, 
1990; Kappel et al, 1991; Mackinnon et al, 1987; Mackinnon et al, 1993; Nieman et 
al, 1989; Nieman et al, 1995; Nieman et al, 1993; Nieman et al, 1991; Nieman et al, 
1990; Nieman et al, 1989; Pedersen et al, 1989; Pedersen et al, 1988; Pedersen et 
al, 1994). In general, detrimental changes to the immune system can be 
documented in response to very high intensity exercise, or excessively prolonged 
exercise bouts (Mackinnon et al, 1987; Mackinnon et al, 1993; Nieman et al, 1992; 
Nieman et al, 1989; Weight et al, 1991 ). 
Food intake may also play a role and poor nutrition could result in an impaired 
immune response (Shephard et al, 1993). Specifically, deficiencies of anti-oxidant 
vitamins, as well as some amino acids, trace elements and essential fatty acids 
have been implicated in impaired host defence (Daly et al, 1990; Peters et al, 1993; 
Peters et al, 1996). 
One of the major limitations of most of the epidemiological studies investigating the 
relationship between symptoms of upper respiratory tract infections and exercise is 
that they have relied on self reported symptoms. The true measure of the outcome 
(URTI) is difficult to ascertain without an adequate clinical examination and 
laboratory documentation of the infection. Symptoms reported by athletes may not 
necessarily be accompanied by infection and may simply be a local inflammatory 
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response to mechanical irritation of the upper respiratory tract (Brenner et al, 1994; 
Peters et al, 1983; Shephard et al 1993). This is based on the observation that most 
symptoms occur within two to three days and are localized to the respiratory tract 
without systemic symptoms (Peters, 1990; Peters et al, 1983; Peters et al, 1993; 
Peters et al, 1996). However, this hypothesis has not been tested in a well 
conducted clinical study. 
Fusafungine is an antibiotic of fungal origin with a potent local anti-inflammatory 
action (German-Fattal, 1995; German-Fattal, 1996). It is administered locally to the 
nasal and pharyngeal mucosa by spray. It can be hypothesised that the 
anti-inflammatory action of fusafungine may decrease the development of mucosa! 
inflammation in such a manner that the incidence of symptoms of upper respiratory 
tract infection may be reduced if it is administered before, during and after 
completion of an ultramarathon. Furthermore, fusafungine could also reduce the risk 
of secondary bacterial infection. The potential value of fusafungine in reducing the 
symptoms of upper respiratory tract infections or the development of bacterial upper 
respiratory infection is the focus of this thesis. 
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Chapter 2 
Literature review: URTI in endurance runners 
2.1. Upper respiratory infections 
2.1.a. Definition 
Upper respiratory tract infections consist of a number of acute illnesses that occur in 
the upper portion of the respiratory tract (Heath et al, 1992). The classification of 
respiratory tract infections as "upper" (affecting the nose and throat) or "lower'' 
(affecting the bronchiolar pulmonary tissue) is an over-simplification as most 
pathogens infect both upper and lower respiratory tracts (Timbury, 1986). Infants 
and children have the highest incidence of upper respiratory tract infection with four 
to eight episodes per year (Heath et al, 1992). In general, the incidence decreases 
with age and adults usually acquire between two and five upper respiratory tract 
infections per year (Heath et al, 1992). 
2.1.b. Aetiology 
The aetiology of upper respiratory tract infections is viral in more than 90% of cases. 
Almost 200 different viruses have been implicated, but Rhinovirus or Coronavirus 
are the most common pathogens (Heath et al, 1992). Other viruses that have been 
implicated include the Parainfluenza, Respiratory syncytial, Influenza, Adena, 
Coxsackie and Echo viruses (Table 2.1 ). 
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The Beta-haemolytic streptococcus is the predominant bacterial cause of upper 
respiratory tract symptoms. Haemophilus influenzae causes acute epiglotitis, otitis 
media and occasionally pneumonia. Streptococcus pneumoniae tends to affect the 
lower respiratory tract predominantly. Other bacterial causes of respiratory tract 
infection include Mycoplasma pneumoniae, Staphylococcus aureus and anaerobes 
(Robinson, 1990). 
Table 2.1: Viruses associated with the common cold. 
VIRUS 
Most common 
Rhino viruses 
Corona viruses 
Common 
Parainfluenza viruses 
Respiratory syncytial viruses 
Influenza viruses 
Less common 
Adenoviruses 
Enteroviruses 
Reoviruses 
- - - ---·- ---
:PRE DO MINA NT SEASONS 
-----+------ . --- ------------
Autumn, mid-spring to summer 
:winter 
1Autumn, spring 
Winter to early spring 
Winter 
L -- -------
All seasons 
Summer, autumn 
Adapted from Hall & McBride, 1989. 
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2.1.c. Pathophysiology 
Transmission of the viruses that cause upper respiratory tract infection usually takes 
place by close contact with an infected person (Heath et al, 1992). Viral particles 
may be suspended in droplets caused by a cough or sneeze and transmitted directly 
to the upper respiratory passages or conjuctiva of a susceptible individual (Heath et 
al, 1992). The virus may also be spread from contaminated surfaces by hand to the 
mucous membranes (self-innoculation) as well as direct transmission from the hand 
of an infected person to the hand of another who may then touch their nasal or 
conjunctiva! mucosa and acquire an infection (Heath et al, 1992). 
2.1.d. Clinical features 
The most common upper respiratory tract symptom complex is that of acute coryza 
(the "common cold"). Typical symptoms include nasal catarrh, cough and sore throat 
with minimal fever and little or no systemic complaints. Other less common 
manifestations of upper respiratory tract infections include, pharyngitis, croup, 
bacterial tracheitis or epiglotitis (Heath et al, 1992). 
2.1.e. Diagnosis 
The diagnosis of an upper respiratory tract infection is made on a typical history, 
clinical examination and isolation of the infective agent. Serology is of limited value 
due to the large number of viruses (and their many serological types) that may 
cause upper respiratory tract infection (Timbury, 1986). Furthermore, the history of 
typical symptoms is confounded in athletes by other factors. Obligatory mouth 
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breathing that occurs during prolonged exercise may cause drying of the respiratory 
mucosa and slowing of ciliary action (Rylander, 1968). Exposure to cold or 
atmospheric pollutants may also cause irritation of the airways. In addition, 
symptoms may arise from a secondary infection or bronchospasm (Brenner et al, 
1994). The true diagnosis of an upper respiratory tract infection should be based on 
clinical findings and laboratory confirmation of infection (Heath et al, 1992). 
2.1.f. Treatment 
In general, because upper respiratory tract infections are caused in the majority of 
cases by viruses and are therefore self-limiting, only symptomatic treatment is 
required (Timbury, 1986). Adequate fluid intake, rest and treatment with analgesics 
and possibly decongestants is all that is required in the majority of cases (Brenner 
et al, 1994; Timbury, 1986). Any secondary bacterial infection should be treated with 
an appropriate antibiotic. The importance of infection in athletes however, is more 
significant with the potential for developing a myocarditis or sudden death in those 
who continue to exercise while infected with a virus. Athletes should therefore be 
advised to follow a suggested "neck check" (Eichner, 1993) when deciding to 
exercise while infected. If all the symptoms are" above the neck" (runny or stuffy 
nose, scratchy throat), the athlete could begin their exercise routine at below normal 
intensity for ten minutes. If the activity made them feel worse, they should stop 
exercising, but if they feel better, they can continue with training. However, if any 
symptoms were "below the neck" (muscle aches, cough, vomiting, diarrhoea or 
fever) training should be discontinued (Eichner, 1993). Exercise should only be 
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started at least fourteen days after the cessation of these symptoms (Heath et al, 
1992). 
2.1.g. Prevention 
The most effective way to prevent infection is to minimise exposure to pathogens 
(Shephard et al, 1993). Athletes should avoid contact with infected individuals 
(especially children) and any team members who have symptoms should be isolated 
from their peers. Since viruses are often transmitted by hand contact, the hands 
should be washed regularly and any rubbing of the eyes or of the nose should be 
avoided (Shephard et al, 1993). 
For those athletes engaged in heavy training further preventative measures include 
spacing vigorous workouts and race events as far apart as possible, eating a well 
balanced diet, keeping life stresses to a minimum, avoiding over-training and 
chronic fatigue and obtaining adequate sleep (Heath et al, 1992). Vitamin 
supplementation (especially vitamin C) may also be beneficial (Peters et al, 1993). 
Lastly, the innoculation of viruses endemic to the area where an athlete will 
compete may be useful (Shephard et al, 1993). lmmunoglobulin that is injected 
intra-muscularly may reduce the incidence, duration and severity of upper 
respiratory tract illness in athletes (Nieman et al, 1991 ). 
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2.2. The effect of exercise on the immune system 
A large number of scientific studies have been performed to determine the effects of 
exercise on the various components of the immune system. In general, detrimental 
changes to the immune system can be documented in response to very high 
intensity exercise or excessively prolonged exercise bouts. 
A wide variety of changes in immune status have been documented in association 
with acute exercise. However, most of these are transient and reverse within hours 
of the exercise bout (Simon, 1987). Changes that occur include alterations in the 
ratio of T-helper to suppressor cells, serum immunoglobulin levels, and the 
proliferative response of the peripheral blood mononuclear cells to standard 
mitogens. 
Immediately after a bout of high intensity exercise a leukocytosis (Nieman et al, 
1992; Weight et al, 1991) can be demonstrated. It has been shown that both 
neutrophils and lymphocytes increase after exercise representing approximately 
60% and 30% of the leukocytes respectively (Nieman et al, 1992). However, after 
approximately an hour, the lymphocyte count decreased to 36% below pre-test 
levels. The immediate post exercise increase in lymphocytes was due to a large 
increase in natural killer cells and a smaller increase in cytotoxic/ suppressor T 
cells. A sharp decrease in total T cells and a moderate decrease in NK cells was 
responsible for the recovery lymphopenia. The lymphocyte count remained low for 
36 hours. These increases in the leukocyte count appear to be as a result of 
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exercise induced increases in serum adrenaline and cortisol concentrations. 
Adrenaline is known to increase the number of leukocytes substantially (Nieman, 
1994 ). In contrast, increased cortisol is known to induce neutrophilia and cause a 
lymphocytopenia (Nieman, 1994). Immediately after exercise, adrenaline serum 
concentrations decrease to pre-exercise serum concentrations while serum cortisol 
concentrations remain elevated resulting in a reduction in the number of leukocytes. 
One component of the immune defences that has shown a more prolonged effect 
from exercise is the natural killer (NK) population (Shephard et al, 1993).The NK 
cells are a heterogeneous but important subset of lymphocytes capable of 
destroying cells that are infected with viruses and other micro-organisms without 
prior exposure. As little as one hour of exercise at 60% vo2 max has been shown to 
reduce NK activity to 50% of normal, with recovery being incomplete two hours later 
(Shephard et al, 1993). More prolonged and intensive exercise, such as a marathon 
run, has left the lytic activity of NK cells depressed the following day (Shephard et 
al, 1993). Various prostaglandins are capable of inhibiting the cytotoxic activity of 
NK cells. It has been demonstrated that the post exercise suppression of NK cells 
may be related to increased serum concentrations of prostaglandins that are 
released from monocytes (Kappel et al, 1991 ). lndomethacin abolished this 
suppressed NK cell activity in vitro (Kappel et al, 1991 ). It has been shown that 
there is a 59% increase in serum cortisol concentrations in well trained marathoners 
who ran their fastest marathon pace on a treadmill for three hours (Berk et al, 1990; 
Nieman et al, 1989). This increase in serum cortisol concentrations correlated 
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inversely with a 25 - 46% decrease in NK cell activity at 1.5 hours after recovery 
which persisted for nearly six hours although serum cortisol concentration returned 
to normal at 1.5 hours. 
The serum concentrations of C3 and C4, but not lgG, lgA or lgM, are decreased 
during rest, graded submaximal exercise, and during recovery in marathon runners 
compared with sedentary controls (Nieman et al, 1989). However, secretory lgA, the 
principle immunoglobulin in local secretions of the mucosal surfaces of the upper 
airways, has been shown to be decreased after intense endurance exercise 
(Mackinnon et al, 1987; Tomasi et al, 1982) and brief supramaximal interval 
exercise (Mackinnon et al, 1993). It has been suggested that low secretory lgA 
levels may result from depletion of nasal fluid and/or malfunction of the mucosa! 
plasma cells due to a decrease in the temperature of the mucous membranes. This 
might lead to an increased susceptibility to viral and bacterial infections, especially 
in the interval immediately following strenuous exercise (Tomasi et al, 1982). 
Besides the fall in secretory lgA, there may also be changes in the physical 
properties of the protective mucous layer, impaired mucocilliary clearance and 
macrophage function during exercise (MacNab et al, 1981 ). Changes in the factors 
protecting the mucosal surfaces such as lysozymes and interferon may also 
increase the risk of upper respiratory tract infection in response to exercise 
(MacNab et al, 1981 ). 
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A further factor that may account for the increased risk of upper respiratory tract 
infections in athletes, is the involvement of the immune system in the tissue repair 
process that occurs following strenuous exercise. It has been well established that 
both high intensity acute exercise bouts and prolonged exercise are associated with 
muscle cell damage, local inflammation and the sequence of host defence reactions 
known as the acute phase response (Evans et al, 1991 ). It is possible that host 
protection from infection may be compromised during the time the immune system is 
involved in tissue repair following high intensity exercise, but this has yet to be 
measured objectively (Nieman, 1994). 
Food intake and poor nutrition may also play a role in impairing the immune 
response (Shephard et al, 1993). In some instances the athlete's diet may fail to 
meet the demands imposed by a high level of energy expenditure and repeated 
depletion of glycogen stores. Deficiencies of many amino acids, trace elements, 
essential fatty acids and vitamins have been associated with impaired host defence 
against infection (Daly et al, 1990; Peters et al, 1993; Peters et al, 1996). 
Finally, psychological factors may also play an important role in the relationship 
between exercise and upper respiratory infections. An intensive exercise program is 
a form of physiological stress (Heath et al, 1992) and the combination may 
compromise the ability of the immune system to protect the host. Mental stress 
alone has been related to a wide variety of negative changes in immune system 
function (Jemmott et al, 1984). 
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Bereavement, major depression, schizophrenia, marital discord and other forms of 
mental stress have all been associated with suppression of immune function 
(Jemmott et al, 1984). 
In conclusion, the effect of combined psychological and physiological stress from 
high intensity endurance exercise, especially during times of competition may lead 
to suppression or down-regulation of the immune system (Heath et al, 1992). 
Based on the observed immunological changes following exercise, an "open 
window" hypothesis has been proposed to account for the increased risk of 
respiratory tract infection following intensive exercise (Pedersen et al, 1994). During 
moderate as well as acute exercise, the immune system is enhanced (Figure 2.1 ), 
but in response to high intensity exercise immunosuppression occurs (Figure 2.2). It 
is during this time that the athlete is at risk for infection by microbial agents, 
especially viruses. However, in those athletes who perform regular moderate 
exercise, the immune system will be enhanced and this may protect from illness. 
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St1mulat1on 
r ' \ Immunity 
I 
' 
j I 
Suppression 
I -
Rest Moderate Exercise Recovery 
Figure 2.1: Immune system response to acute moderate intensity 
exercise. 
Adapted from Pedersen and Ullum, 1994. 
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Stimulation 
r 
Immunity 
j · 11//II/I 
'open window" 
. I I Suppression 
I 
-- _t__. - -
Rest High Intensity Exercise Recovery 
Figure 2.2: "The open window" hypothesis. Immune system 
response to acute high intensity exercise. 
Adapted from Pedersen and Ullum, 1994. 
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2.3. Epidemiology and risk factors of URTI in endurance runners 
A number of scientific studies have shown that endurance athletes are at increased 
risk for developing symptoms of upper respiratory tract infection (Nieman et al, 
1990; Peters, 1990; Peters et al, 1983; Peters et al, 1993; Peters et al, 1996). This 
is especially so at times of intense training and during the two week post-race 
period. 
The first investigators to demonstrate this increased risk for the development of 
upper respiratory tract symptoms after an ultradistance event were Peters and 
Bateman (Peters et al, 1983) in their study at the 1982 Two Oceans ultramarathon 
(56km). One hundred and fifty race finishers were compared with age-matched 
non-running controls. The runners completed a questionnaire on the day before the 
race and both the runners and controls were questioned regarding the development 
of upper respiratory tract symptoms during the fourteen day post race period. Nine 
athletes failed to complete the race and were excluded from the trial. Of the 
runners, 33.3% reported symptoms of upper respiratory tract infections during the 
two week post-race period compared to 15.3% of the control group. The most 
prevalent symptom after the race was sore throat ( 41 % ), followed by nasal 
symptoms (36%), including a runny nose and/or sneezing. A cough was less 
common ( 19%) and only three subjects developed fever in conjunction with one or 
more of the upper respiratory tract symptoms (Table 2.2). In this study, 80% of the 
affected runners developed symptoms which lasted for more than three days, and 
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the investigators suggested that an infective process was responsible for the 
symptoms. 
Table 2.2: The nature and duration of upper respiratory tract 
symptoms after an ultramarathon run at sea level. 
_ _ Dur~tion <:>f symp!oms lci_ays}_ 
~ymptom~~< 1 d~y 1 -_3_days, 4- 7 day~ .. > 7 da_y~ __ Total % Total 
------- - -----
Sore throat 6 2 12 12 32 41 
28 
36 
Nasal 
syrlJJ)tom~_ 1 5 8 14 
- ----- -
15 19 C.9_ugh 1 0 5 9 -- -
Fever with 
upper 
respiratory 0 0 1 2 3 4 
tract 
symptoms ... 
Total 8 7 26 37 78 100 
Adapted from Peters et al, 1993. 
The incidence of upper respiratory tract symptoms was the highest in the fastest 
runners (p < 0.01) with 47% of runners who finished in less than four hours 
reporting symptoms (Figure 2.3). 
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50 
- 40 -::R 0 
.......... 
(]) 
0 30 
C 
(]) 
"C ·-0 20 
C 
10 
<4h 4h -4h30 4h30-5h 5h-5h30 5h30-6h 
Race time (hours) 
Figure 2.3: The incidence of upper respiratory tract symptoms 
according to time taken to complete the race (n = 141). 
Adapted from Peters et al, 1983. 
There was significant association (p < 0.01) between symptoms and high weekly 
training distance. Athletes who were training more than sixty five kilometres per 
week were at greater risk of developing upper respiratory tract symptoms (Table 
2.3). 
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Table 2.3: Upper respiratory tract symptoms in relation to training 
distance per week before the race (n = 141). 
Symptomatic runners Asymptomatic runners 
< 65km/wk 
> 65km/wk 
9 
38 
Adapted from Peters and Bateman, 1983. 
36 
56 
The investigators suggested that the higher incidence of upper respiratory tract 
symptoms in the immediate post-race period can be attributed to one or both of the 
following: (1) the impairment of general host resistance to infection resulting from 
the extreme stress and fatigue of running an ultramarathon or (2) the physical 
affects of cold and dry air on local mucosal defences. The investigators also point 
out that local trauma may occur to the mucous membranes as a result of mouth 
breathing. The increased minute ventilation required during submaximal exercise 
may be responsible for or contribute to this trauma. In an ultramarathon, this may 
continue for four to five hours or longer. Based on these assumptions, Peters 
(Peters, 1990) repeated the study at another 56 kilometre ultramarathon. This 
marathon however, took place at altitude(± 1600 metres above sea level) and a 
relative humidity of 52%. This is lower than the relative humidity at sea level, (79%). 
It was hypothesised that the amount of damage to the mucous membranes should 
19 
be greater at altitude due to drier inhaled air and the increased ventilation at a given 
running speed. 
The methodology was the same as in the previous study. Thirty one (28. 7%) of the 
one hundred and eight subjects who completed the race reported non-allergy 
related upper respiratory tract symptoms during the two weeks following the race as 
compared to fourteen ( 12%) among the control group. This was a significantly 
higher incidence (p < 0.005). The most prevalent symptoms after the race were 
blocked or runny nose (57%), followed by a sore throat (30%). Thirty nine percent of 
the symptoms lasted for more than seven days and only two runners reported fever 
accompanying the symptoms (Table 2.4). 
Table 2.4: The nature and duration of respiratory tract symptoms 
after an ultradistance race at altitude (n = 46). 
Duration of symptoms {days) 
.... ·-· .. .. •·······• ··-····-~··········----··--··----···------ ···-··-··· 
Symptoms < 1 day · 1 - 3 days: 4 - 7 days > 7 days Total % Total 
Nasal 4 · · 9 · T - 2 · · 11 · 26. · 57 ··-·· 
Sore throat 
Cough ..... . 
Fever 
Total 
0 
0 
0 
4 
9 
0 
19 
Adapted from Peters, 1990. 
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This study confirmed their previous findings of a significantly higher incidence of 
upper respiratory tract symptoms amongst runners compared to matched sedentary 
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controls following participation in an ultradistance marathon event. However, in this 
study the exposure to moderate altitude with the concomitant increase in pulmonary 
ventilation and drier air did not result in an increased incidence of upper respiratory 
tract symptoms compared to runners at sea level (Figure 2.4). These results appear 
to indicate that altitude and relative humidity do not influence the incidence of upper 
respiratory tract symptoms after ultradistance running. 
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Figure 2.4: A comparison of the incidence of URT symptoms 
amongst runners and controls at moderate altitude 
(1800m) and sea level. 
Adapted from Peters, 1990. 
21 
In this second study, there was also a higher incidence of symptoms(± 32%) 
amongst the faster athletes. Furthemore, athletes who took longer than six hours to 
complete the race also showed increased incidence of upper respiratory tract 
symptoms. It appears that prolonged physiological stress may also decrease host 
resistance and predispose to the development of symptoms. This study also showed 
that the less trained runners had the highest incidence of symptoms. 
Vitamin C is an anti-oxidant that may reduce the risk of developing respiratory tract 
infection (Anderson et al, 1972; Baird et al, 1979; Bucca et al, 1989; Chalmers, 
1975; Hodges et al, 1980; Mink et al, 1988; Schwartz et al, 1990). Exercise 
increases the production of oxygen free radicals which may depress immune 
function by inhibiting leukocyte chemotaxis (Kanter et al, 1988; Packer, 1986). It is 
therefore possible that anti-oxidants, including Vitamin C, may be required in high 
doses in athletes to oppose the effect of these free radicals (Anderson, 1984; 
Bendich et al, 1986). A study (Peters et al, 1993) was conducted to determine 
whether daily supplementation with 600mg Vitamin C would reduce the incidence of 
upper respiratory tract infections after an ultramarathon. Ninety two runners who 
entered the 1990 Comrades Marathon (90km) nominated a control non-running 
subject of similar age. A double-blind placebo controlled study was conducted in 
which half the runners and controls were required to take 600mg of Vitamin C daily 
for twenty one days prior to the marathon while the remaining runners and controls 
ingested placebo. Each subject completed a questionnaire prior to the race 
documenting demographic data regarding their running history. The runners were 
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asked to detail all forms of vitamin or mineral supplementation and a 24 hour dietary 
recall was used to establish their daily dietary intake. Two weeks after the race the 
subjects were questioned by telephonic interview regarding the development and 
duration of symptoms (nasal, sore throat, cough and fever) of upper respiratory tract 
infection. Total Vitamin C intake was calculated in each subject and in those runners 
who took supplements of 600mg Vitamin C, their total daily Vitamin C intake was in 
excess of 1 g. The Vitamin C supplemented groups of runners and the age matched 
control subjects had significantly higher daily Vitamin C intakes (1139g ± 452) when 
compared with runners (494g ± 390) and their controls (280g ± 202) who received 
placebos (p < 0.01 ). 
During the two week post-race period, significantly fewer subjects (33% vs. 68%; 
p < 0.01) who were supplemented with Vitamin C reported symptoms of upper 
respiratory tract infection (Figure 2.5). 
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Figure 2.5: The incidence of symptoms of URT infection in runners 
and non runners (controls) receiving either 600mg 
Vitamin C or a placebo. Significant difference (* p < 0.05). 
Adapted from Peters et al, 1993. 
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In this study, the incidence of symptoms was greatest in those who fell into a high 
training status group (Figure 2.6). The training status ratio of each runner was 
calculated using the following formula: 
Weekly training distance (km) x no. of weeks spent in training 
average speed at which those kilometres were covered 
Runners who reported a ratio of > 450 constituted the high-training status category, 
whereas those with a ratio < 300 were classified in the low-training status catagory 
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Figure 2.6: The incidence of post-race URT symptoms in low, 
medium and high training status groups (n = 77). 
Significantly different (* p < 0.01) from percentage 
symptomatic in the low and medium training status 
groups. 
Adapted from Peters et al, 1993. 
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There was however no correlation between the time in which the race was 
completed and the reported incidence of symptoms. In a subsequent study at the 
1993 Comrades Marathon (Peters et al 1996), compared the efficacy of 
supplementation with combinations of Vitamin E, Vitamin C and Beta Carotene 
versus Vitamin C alone in reducing symptoms of post-race upper respiratory tract 
infection. 
A double-blind, placebo controlled study design was used in which runners (n = 
178) and sedentary matched controls (n = 162) were randomly divided into groups 
receiving 500mg Vitamin C (n = 86), 500mg Vitamin C and 400iu Vitamin E (n = 90) 
or 300mg Vitamin C, 300iu Vitamin E and 18mg Beta Carotene (n = 73) or placebo 
(n = 95) daily for twenty one days prior to participation in the event. The pre-race 
training status, state of health and dietary vitamin and mineral intake of the athletes 
and their age matched controls were recorded by means of a questionnaire 
completed prior to the race. Runners with a history of allergies were excluded. The 
total pre-race vitamin intakes were calculated from the dietary intake, additional 
supplements taken by the athletes and the anti-oxidants given to the subjects. 
Two weeks after the race, all participants were telephonically questioned regarding 
their compliance to the trial as well as the incidence and duration of the upper 
respiratory tract symptoms. Only reports of single upper respiratory tract symptoms 
lasting more than a day or a combination of at least two upper respiratory trace 
symptoms each which lasted less than a day were included in the final analysis. The 
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difference between the incidence of symptoms of infection in the runners ingesting 
placebo (40.4%) and the sedentary matched controls (24.4%) was not significantly 
different. The lowest incidence of symptoms of infection was reported in the Vitamin 
C group (15.9%) and this was significantly different from the placebo group 
(p < 0.05). This group reported a Vitamin C intake of 1004mg. The incidence of 
symptoms in the Vitamin C, E and Beta carotene group (20%) was also significantly 
lower than the placebo group. However, the incidence of symptoms in the Vitamin C 
and E group was not significantly different from that in the placebo group 
(Figure 2. 7). 
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Figure 2.7: The incidence of symptoms of URT infection in runners 
(n = 178) and controls (n = 162) during the 14 day post 
race period. (Group C = Vitamin C 500mg, Group CE = 
Vitamin C 500mg & Vitamin E 400iu, Group CEB = 
Vitamin C 300mg, Vitamin E 300iu & Beta Carotene 18mg 
and Group P = placebo). Significant difference: *p < 0.05 
(runners versus controls). 
Adapted from Peters et al, 1996. 
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The findings of this study indicate that large intakes of Vitamin C alone (> 1000mg) 
are more effective than combinations of Vitamin E, Vitamin C and beta carotene in 
decreasing the incidence of symptoms of upper respiratory tract infection in 
ultradistance runners. In this study, no relationship between running time and 
incidence of upper respiratory tract symptoms was documented. Training status 
appeared to be an important factor and the highest incidence of symptoms was 
documented in runners who had done the least pre-race training (Figure 2.8) . The 
training status ratio of each runner was calculated using the following formula: 
Weekly training distance (km) x no. of weeks spent in training 
average speed at which those kilometres were covered 
Runners who reported a ratio of> 450 constituted the high-training status category, 
whereas those with a ratio< 300 were classified in the low-training status category. 
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Figure 2.8: The incidence of post-race URTI symptoms in low, 
medium and high training status groups (n = 176). 
Adapted from Peters et al, 1996. 
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An epidemiological survey investigating the relationship between self reported 
symptoms of infections, training data and participation the race has been conducted 
on applicants of the Los Angeles Marathon (Nieman et al, 1990). Eight days before 
the marathon, 4 926 of the 12 200 applicants were randomly selected and a 
previously validated 4-page questionnaire was sent to the subjects. There were 2 
311 respondents (46.91 %) and the study matched for age, marital status and 
reported sickness in other members of the runner's home. The main finding of the 
study was that 12. 9% of participants reported an infectious episode in the week 
following the race compared to 2.2% of the control group of runners with similar age 
and marital status who did not participate (Figure 2.9). It was also shown that 
runners training more than ninety six kilometres per week were twice as likely to 
develop an infectious episode compared to those training less than thirty two 
kilometres per week in the two month pre-race period. The results therefore suggest 
that runners have an increased risk of developing an infectious episode during high 
intensity training or following a marathon race. 
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Figure 2.9: Self-reported URT infection in 2 311 Los Angeles 
marathon runners during the week following the 1987 
Los Angeles Marathon. 
Adapted from Nieman et al, 1990. 
This tendency towards an increased incidence of upper respiratory tract symptoms 
in endurance runners has not however been found in events shorter than 42 
kilometres. The incidence of infectious episodes in 273 runners two months before 
and one week after a 5km, 10km and 21 km race in California has been investigated 
(Nieman et al , 1989). It was found that 25% of runners training more than twenty five 
kilometres per week reported at least one infectious episode as compared with 
34.3% of runners training less than twenty five kilometres per week (p = 0.09). Only 
6.8% of the runners preparing for the half marathon reported illness as compared to 
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17.9% of the 5km and 10km runners (p = 0.067). During the week following these 
races, runners did not report an increase incidence of infectious episodes compared 
with the week prior to the race. It was concluded that runners with a more serious 
commitment to regular exercise were less likely to develop infectious episodes than 
recreational runners. In addition, participating in a 5, 10 or 21 km race did not 
appear to increase the risk of acquiring upper respiratory tract infection (Nieman et 
al, 1989). 
Other studies (Heath et al, 1991; Nieman 1990; Nieman 1993) have investigated the 
relationship between long term training and the risk of developing symptoms of 
upper respiratory tract infection in runners. A cohort of five hundred and thirty male 
and female runners were followed up over a period of twelve months (Heath et al, 
1991 ). The aims of the study were firstly, to document the incidence of upper 
respiratory tract infection, secondly, to examine possible risk factors associated with 
the development of infection and thirdly, to document the association between the 
amount of running and racing experience to infection in the athletes. Information 
about their illness was collected by self-report and runners were asked to indicate 
each day whether they had any of the following symptoms: cold (runny nose, sore 
throat or cough), allergy (itchy eyes or stuffy nose), headache, fever, nausea, 
vomiting, diarrhoea, fatigue/tiredness, muscle/joint/bone problem or injury and 
menstrual cramps. It is important to emphasise that the analyses were based on self 
reported symptoms and that subsequent studies could be strengthened by 
confirming the diagnosis of illness as well as measuring the immune status. 
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The outcome measure for the analysis was an upper respiratory tract infection 
defined as self reported symptoms (runny nose, sore throat or cough) for two 
consecutive days. An episode was considered to be a new upper respiratory tract 
infection if it was separated from a previous upper respiratory tract infection by at 
least three days without any respiratory symptoms. Episodes that were due to 
allergy or chronic respiratory symptoms were not considered as an infection and 
excluded from the analysis. Risk factors related to the runners were investigated 
and included number of days run per week, number of miles run daily and annually, 
racing history and marathon participation.In addition, age, gender, marital status, 
smoking status, alcohol use, breakfast habits, vitamin use. dietary supplements, 
sleep, number of people in the household and body mass index were also 
considered as potential risk factors for the development of upper respiratory tract 
symptoms. 
The average number of upper respiratory tract infections per person per year for the 
cohort was 1.2. Upper respiratory tract infection was indicated by the presence of 
any of the following symptoms: runny nose, sore throat or cough. The lowest odds 
ratio for upper respiratory tract infection was documented in those athletes running 
less than sixteen kilometres per week. The odds ratio more than doubled for those 
running more than twenty seven kilometres per week, demonstrating that total 
annual running distance was a significant risk factor for upper respiratory tract 
symptoms. The risk of upper respiratory tract infection increased as weekly running 
mileage increased. Runners living alone were also found to be at increased risk for 
32 
upper respiratory tract infection. A BMI (body mass index = weight in kg / height in 
m2) greater than the 75 percentile was associated with a smaller likelihood of 
having an event, as was being male. Finally, the association between alcohol users 
and upper respiratory tract infections was positive in males and negative in females. 
Lack of vitamin intake, not eating breakfast, smoking and sleeping either less than 
seven or greater than eight hours a night were unrelated to the incidence of upper 
respiratory tract infection in this study. 
Further evidence that the risk for developing symptoms of upper respiratory tract 
infection may be related to the volume of training may be found in two other studies 
(Nieman et al, 1993; Nieman et al, 1990). In a randomised controlled study (Nieman 
et al, 1990), thirty six mildly obese inactive women performed five, forty five minute 
walking sessions per week for fifteen weeks. This resulted in a significant reduction 
(p < 0.05) of self reported upper respiratory tract symptoms in the active group 
compared with a sedentary control group with less than 50% of the number of days 
with symptoms in the active versus the control group (Figure 2.10). 
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Adapted from Nieman et al, 1990. 
In another study, a group of highly conditioned (n = 12) elderly female subjects 
exercised moderately on a daily basis for about one and a half hours. They were 
compared over a twelve week period to a group walking for forty minutes, five times 
per week (n = 14) and a control group who participated in calisthenic exercises 
(n = 16) only. Using a daily log of self reported upper respiratory tract symptoms, the 
lowest incidence (8%) was documented in the highly conditioned training group. 
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The walkers reported an incidence of 21 %, whereas the control group had the 
highest incidence of 50% (Figure 2.11 ). The study therefore suggests that moderate 
exercise may improve immune function and decrease the risk for developing 
symptoms of upper respiratory tract infection. 
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Figure 2.11: The incidence of URT infection(% of subjects with 
symptoms) during a 12 week study in highly 
conditioned, walking, and sedentary control groups 
of elderly women 
Adapted from Nieman et al, 1993. 
It has been suggested that the relationship between exercise and upper respiratory 
tract infection is "J" shaped (Nieman, 1994), where the risk of upper respiratory tract 
infection is at the lowest in someone engaging in moderate exercise training (Figure 
2.12). The risk then rises in subjects performing excessive amounts of high intensity 
exercise. 
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Adapted from Nieman, 1994. 
The "J" shaped relationship between exercise and the risk of URTI seems to be less 
consistent in studies reported in athletes other than runners. One hundred and 
twenty one male and fifty three female cross country skiers, either members of the 
Swedish national teams or young elite skiers studying at sports college, were 
studied for a twelve month period (Berglund et al, 1990). The frequency, types of 
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infection, and to what extent they caused absence from training was investigated. 
All types of infectious disease that caused absence from training for 3 days or more 
were included. The diagnosis was made by a medical doctor in 29% of cases, a 
coach in 4%, and by the athletes themselves in the remaining 67% of cases. Upper 
respiratory tract infection was the most common infection causing absence from 
training (92.3%). There was however, no significant incidence of infection between 
the world class cross country skiers (1.5 infections per subject per year) and the 
young elite skiers (1.88 infections per subject per year). Furthermore, the incidence 
was similar to that in the general population. 
The incidence of upper respiratory tract infections was also studied in a group of 44 
elite orienteers and 41 non-athletes who were matched for age, sex and occupation 
(Linde, 1987). This was a prospective study which was conducted over one year 
with the subjects diarising self-reported symptoms. The orienteers reported 2.5 
episodes of upper respiratory symptoms per year which was significantly higher (p < 
0.05) than the 1.7 episodes reported by the non-athlete group. The symptoms also 
lasted longer in the orienteers compared with the control group (7.9 days vs. 6.4 
days). One third of the controls reported no infection during the study period, while 
only 10% of orienteers reported no infection. The orienteers also showed a more 
equal distribution of illness over the year when compared to the non-athletes who 
showed the typical winter peak. The relationship between the incidence and 
duration of symptoms of upper respiratory tract infection and the habitual level of 
physical activity in 92 men and 107 women participating in the Amsterdam Growth 
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and Health study has also been reported (Schouten et al, 1988). The weekly "dose" 
of physical activity was quantified as the product of duration of exercise (min/week) 
and weekly energy expenditure (measured as METs/week). A limitation of the study 
was that the upper respiratory tract infection measurement relied on memory recall 
over the past six months. When comparing groups by total energy expenditure, level 
of sports activity or maximum aerobic power, no difference in the incidence or 
duration of upper respiratory tract symptoms was documented. However, a slight 
negative correlation between the incidence of symptoms and a moderate level of 
sports participation in female participants was reported. 
In a prospective study conducted on twelve year old children (n = 62) participating 
in swimming, ice hockey and gymnastics four times a week, no difference in the 
incidence of infection between these children and an age-matched controlled group 
were reported (Osterback et al, 1987). 
The prevalence of illness and absence in members of three men's intercollegiate 
athletic teams (wrestlers, swimmers and gymnasts) was also studied (Strauss et al, 
1986). Members (n = 87) were interviewed weekly over eight weeks. Eighty six 
percent of the athletes had at least one respiratory illness during the study period. 
The study was conducted during the peak season (winter) for respiratory illness. 
There were no significant differences among teams for respiratory problems. One of 
the major limitations of this study was that there was no control group of 
non-athletes. 
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In summary, epidemiological studies in ultradistance runners show that these 
athletes are at increased risk for developing symptoms of upper respiratory tract 
infection during times of intense training and especially so, in the two weeks after an 
ultramarathon event. These findings have been largely based on self-reported 
symptoms, either by questionnaire or telephonic interview, without a clinical or 
laboratory diagnosis of actual infection. Athletes that engage in moderate activity do 
not appear to be at increased risk for upper respiratory tract infection and in some 
instances may show resistance to the development of upper respiratory infection. 
2.4. Fusafungine and the prevention or treatment of upper respiratory tract 
infection 
Fusafungine is an antibiotic of fungal origin which is extracted from Fusarium 
literatum WR, strain 437. It has three fundamental pharmacological properties: 
1. It is a local antibiotic adapted to the treatment of respiratory tract infections 
with antimicrobial activity against the majority of bacteria responsible for 
these infections (German-Fattal, 1996). In addition, it has an anti-fungal 
action (which limits the risk of secondary candidiasis). 
2. It has a potent anti-inflammatory action which reduces oedema and 
exudation thereby relieving inflammatory obstruction and pain 
(German-Fattal et al, 1995; Gosset et al, 1996). As this action is intrinsic to 
the drug, without the addition of corticosteroids and vasoconstrictors, there is 
no risk of a rebound effect or habituation. 
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3. It is a true micronised aerosol with micron-sized particles that diffuses 
throughout the respiratory tract, deeply penetrating and lining the mucous 
membranes (Newman, 1995). It has no systemic effects. 
It can be hypothesised that the local anti-inflammatory and the local anti-microbial 
action of fusafungine may reduce the incidence of upper respiratory tract infection in 
runners prior to and after completion of an ultramarathon. Although upper 
respiratory tract infections are most commonly caused by viruses, fusafungine would 
also be expected to have an effect on the development of secondary bacterial 
infection. The anti-inflammatory action may also reduce upper respiratory tract 
symptoms as opposed to infection and this would also have to be considered when 
assessing its overall effect. 
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Chapter 3 
The effect of fusafungine on the incidence of upper respiratory tract infection 
in ultradistance runners 
3.1. Introduction 
Ultradistance athletes have been shown to have increased incidence of upper 
respiratory tract symptoms after an event (Nieman et al, 1990; Peters, 1990; Peters 
et al, 1983; Peters et al, 1993; Peters et al, 1996). This increased incidence has 
been documented by self reported symptoms without clinical examination or 
laboratory documentation of infection (Nieman et al, 1990; Nieman et al, 1991; 
Peters et al, 1983; Peters et al, 1993; Peters et al, 1996). Furthermore, it has been 
shown that faster athletes(Peters, 1983) and those who have trained harder were 
more at risk for developing symptoms (Heath et al, 1991; Nieman et al, 1990; Peters 
et al, 1983; Peters et al, 1993). 
Various investigators have studied the relationship between exercise and immune 
function. In general, detrimental changes to the immune system can be documented 
in response to very high intensity exercise, or excessively prolonged exercise bouts 
(Mackinnon et al, 1987; Mackinnon et al, 1993; Nieman et al, 1992; Nieman et al, 
1989; Weight et al, 1991 ). However, no specific immunological marker has been 
found to account for this increased incidence of upper respiratory tract symptoms in 
ultradistance runners. 
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Fusafungine has both antibacterial and anti-inflammatory properties and may be of 
benefit to decrease the incidence of upper respiratory tract symptoms and infections 
in ultradistance runners. This study was conducted to determine whether the use of 
fusafungine before and after an ultradistance event would reduce the incidence of 
respiratory tract symptoms in the athletes. In addition, evidence of true infection as 
opposed to symptoms was sought by means of clinical examination and laboratory 
documentation of the infective agent. 
3.2. Aim of the study 
The aim of this study was to determine whether the use of a topical 
anti-inflammatory/antibacterial agent (fusafungine) will decrease the incidence of 
respiratory tract infections and respiratory tract symptoms before and after an 
ultradistance running event. 
3.3. Methodology 
3.3.a. Type of study 
This study was conducted as a randomised double blind placebo controlled clinical 
trial. The subjects of the study were familiarised with the details of the clinical trial 
and signed informed consent was obtained. Ethics and Research Committee 
approval by the Ethics and Research Committee of the University of Cape Town 
was obtained prior to the onset of the study. 
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llb. Subject recruitment 
A homogeneous group of male runners (n = 96) who took part in the 1996 Two 
Oceans Ultramarathon (56 kilometres) were recruited by convenience sampling for 
the study. The following inclusion criteria applied: 
-Runners who have either completed a 56 kilometre ultramarathon in less than five 
and a half hours or a marathon qualifying time of less than three and a half hours. 
-Runners with a body mass index (BMI) of less than the 75th percentile. 
-Runners with no history of severe illness requiring long term medication. 
-A history of restricted use of anti-oxidants. This was defined as runners who do not 
consume large doses of anti-oxidant supplements on a daily basis (Vitamin C 
< 1000mg, Beta Carotene< 18mg and Vitamin E < 400IU). 
3.3.c. Dietary food and supplement intake 
A three day dietary analysis was performed on a randomly selected sub-group of 
runners (n = 44) to document their intake of nutrients, in particular, anti-oxidants. 
The subjects were instructed to document all foods, fluid and vitamin or mineral 
supplements that were consumed for three consecutive days (Appendix 3). A three 
day food diary was used as opposed to a five or seven day diary to ensure a high 
compliance from participants. The subjects were asked to quantify all foods and fluid 
consumed in standard serve sizes such as cups, tablespoons or teaspoons. Protein 
foods were described according to actual weight or in terms of their size in relation 
to the number of match boxes. Food preparation and method of cooking were also 
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taken into consideration to ascertain the fat content of foods. On completion of the 
food diaries, all subjects were then telephoned after the event to verify the 
standardised food servings and quantities documented. The three day food records 
were then analysed by a sports dietician and converted into nutrients using the 
Food Fundi Professional (Penta Medical Systems, Johannesburg, South Africa) 
computer program. 
3.3.d. Administration of medication 
The original group of runners (n = 96) was randomly allocated to either a group 
receiving active medication (fusafungine) (active group) or a group receiving 
placebo medication (control group) in a double blind manner. All the runners 
completed a pre-race questionnaire one week before the event (Appendix 1 ). This 
questionnaire provided details regarding the personal details of the runner, training 
history and medical history including history of previous upper respiratory tract 
infections. 
Active and placebo medication in identical containers were pre-packed and labelled 
by the pharmaceutical company (Servier Laboratories, P.O. Box 930, Rivonia 2128, 
Republic of South Africa). Both the subjects and the investigators were blinded with 
respect to the medication they received or administered. The code was kept sealed 
and only revealed once statistical analysis was complete. Subjects who complained 
of symptoms of upper respiratory tract infection on entry to the trial were excluded 
from further participation. 
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Subjects were required to self-administer the spray for two days prior to (Days -2 to 
-1) and for nine days after the race (Days 0-9). The dosage was four sprays into 
each nostril four times daily, and four sprays into the throat while inhaling, also four 
times daily in order to obtain the best possible compliance. The subjects were 
familiarised with the proper use of the spray, by carefully instructing them, and by 
providing them with a standardised instructional pamphlet. The subjects completed 
a patient diary on a daily basis, documenting their dosage administration over the 
twelve day period, as well as the development of respiratory tract symptoms 
(Appendix 2). The sequence of events is summarised in Figure 3.1. 
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,--
l Pre-race assessment ( one week prior to the race) 
!
General medical history, clinical examination and inclusion in the trial (n = 96). 
!
Medicine dispensed, patient diary A and dietary questionnaire handed out to the 
subjects. 
I ~ 
, Day six assessment (three days after the race) 
I 
Patient diary A returned. Clinical examination of athletes with symptoms. Patient 
diary B handed out to subjects. 
Day twelve assessment (nine days after the race) 
Patient diary B returned. Clinical examination of athletes with symptoms. 
Dietary questionnaire returned. 
Figure 3.1: Methodology: Subject assessment (pre- and post-race). 
Adequate compliance to medication use was defined as> 70% of all the dosages of 
the active medication (active group) over the treatment period. After the study was 
completed, subjects who recorded less than 70% administration of all the dosages 
over the treatment period were excluded from the active group. Six subjects were 
excluded from the active group because of poor compliance. The final group 
numbers were therefore as follows; Active (n = 42), and Control (n = 48). 
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Running intensity in the two groups was determined by the average 
minutes/kilometre during training, and the final running times for the fifty six 
kilometre ultradistance event. These parameters were recorded and compared 
between the two groups. 
3.3.e. Incidence of respiratory tract infections and symptoms 
All the subjects were required to report any symptoms of respiratory tract infections 
(upper and lower) to the investigators. Once a runner presented with any symptom, 
the runner visited the laboratory where a clinical history and examination was 
conducted. All the subjects who presented with a sore throat were subjected to a 
throat swab and a viral gargle. The throat swab was cultured and inoculated for 
bacteria in a standard microbiology laboratory (Ors. Dietrich, Street and Partners, 
Cape Town). Using a large blood agar plate with a bacitracin disc and incubated at 
37 °C (anaerobic culture). Furthermore, a Todd-Hewitt broth was incubated at 37 °C 
(aerobic culture) and a subculture Todd-Hewitt broth onto blood agar with a 
bacitracin disc after 18 hours. 
A solution for the viral gargle (7,5% sucrose, 1 OOmmol phosphate buffer and 
0,002% phenol red) was obtained from the Department of Virology of the University 
of Cape Town, Medical School. Each symptomatic subject gargled thoroughly with 
the solution which was then returned to the bottle and transported on ice to the 
laboratory. Each sample was innoculated into duplicate primary African Green 
Monkey kidney cell cultures and incubated and observed for 10 days. At the end of 
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this period the cultures were tested for Haemadsorption properties with guinea pig 
red blood cells. Coverslip cultures were stained and examined by microscopy for 
viral cytopathic effects (Prof. Moodie - personal communication). 
For the purpose of this study, athletes who presented with symptoms but negative 
viral or bacterial cultures, were classified as "athletes with respiratory tract 
symptoms but no infections", and athletes with generalised symptoms (malaise, 
fever, headaches) and a positive throat swab or a positive viral culture were 
regarded as "athletes with respiratory tract infections". 
Symptoms that were recorded were blocked nose, runny nose, sore throat and 
cough. In order to make comparisons to previously published studies, symptoms 
were subdivided into nasal symptoms (blocked nose and runny nose), upper 
respiratory tract symptoms (blocked nose, runny nose and sore throat) and all 
respiratory tract symptoms (blocked nose, runny nose, sore throat and cough). 
3.3.f. Statistical analysis of data 
Statistical analysis was conducted at the Institute for Biostatistics at the Medical 
Research Council, in Parow, Cape Town. Standard descriptive statistics were used 
to document the characteristics of the groups, and the Chi-square test or the 
Fisher's exact test were used to determine whether significant differences in 
frequencies of variables occurred between the two groups. The level of significance 
was established at p < 0.05. 
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3.4. Results 
3.4.a. Subject characteristics 
The physical characteristics, training history and running intensity of the subjects 
that were recruited for the study (active and placebo groups) are depicted in Table 
3.1. There were no significant differences between the two groups with respect to 
age, weight, height, weekly training (km/week) and running intensity (running speed 
and finishing times). There were also no significant differences between the two 
groups with respect to the frequency of a past history of respiratory disorders, hay 
fever, asthma, smoking and average number of respiratory tract infections per year. 
The dietary intake of energy, fat, protein, carbohydrate, Vitamin A, Beta carotene, 
Vitamin C and Vitamin E was not significantly different between groups (Table 3.2). 
3.4.b. Incidence of respiratory tract symptoms 
The incidence of a blocked nose in the two groups of ultradistance runners is 
depicted in Figure 10. There was no significant difference in the incidence 
(incidence per 100 runners) between the active and the placebo groups for the three 
time periods that were studied. 
The incidence of a runny nose in the ultradistance runners in the three times 
periods that were studied is depicted in Figure 3.3. There was no significant 
difference in the incidence of a runny nose in the two groups in any of the time 
periods that were studied. 
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The incidence of a sore throat in ultradistance runners in the three time periods that 
were studied is depicted in Figure 3.4. There was no significant difference in the 
incidence of sore throat between the two groups in any of the time periods that were 
studied. 
The incidence of a cough in ultradistance runners in the three time periods that 
were studied is depicted in Figure 3.5. There was no significant difference in the 
incidence of cough between the two groups in any of the time periods that were 
studied. 
The incidence of nasal symptoms (blocked nose or runny nose) in ultradistance 
runners in the two groups over the three time periods that were studied is depicted 
in Figure 3.6. There was no significant difference in the incidence of nasal 
symptoms between the two groups in the time periods day -2 to -1, and day 4-9. 
However, there was a tendency for a significant decrease (p = 0.085) in nasal 
symptoms in the active group in the time period 0-3 days after the ultradistance 
race. 
The incidence of all respiratory tract symptoms (blocked nose, runny nose or sore 
throat) in ultradistance runners in the three time periods in the two groups that were 
studied is depicted in Figure 3.7. There was a significantly lower (p = 0.025) 
incidence of upper respiratory tract symptoms in the active group (17%) compared 
to the control group (40%) in the time period Oto 3 days after the race. There was 
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no significant difference in the incidence of upper respiratory tract symptoms in the 
two groups in days -2 to -1 (before the race) and in days 4 to 9 (after the race). 
The incidence of all respiratory tract symptoms in ultradistance runners in the three 
time periods that were studied is depicted in Figure 3.8. There was a significantly 
lower incidence of respiratory tract symptoms in the active group compared to the 
placebo group in the time period Oto 3 days after the race (p = 0.028). There was 
no significant difference in the incidence of respiratory tract symptoms in the two 
groups in the time period -2 to -1 (before the race) and day 4 to 9 (after the race). 
The incidence of all post-race respiratory tract symptoms in the ultradistance 
runners in the time period day Oto 9 after the race is depicted in Figure 3.9. There 
was no significant difference in the incidence of all post-race respiratory tract 
symptoms between the two groups. 
In none of the subjects presenting with a sore throat, were positive bacterial or viral 
cultures documented. Therefore the incidence of upper respiratory tract infections is 
zero. 
3.4.c. Incidence of clinical findings 
Twelve subjects presented with symptoms at the day six assessment. No athlete 
had either an elevated temperature or pulse rate. Eight had a mild pharyngitis and 
all had clear lungs on physical examination. One subject presented on day twelve 
with mild pharyngitis and ronchi at the left lung apex. His temperature and pulse rate 
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were normal. 
3.4.d. The effect of training volume and finishing times on the incidence of 
respiratory tract symptoms 
The runners (n = 96) were grouped into those who had any symptoms irrespective 
on which day (n = 48) and those who were symptom-free (n = 48). The 
symptom-free athletes did significantly (p < 0.05) less training than those with 
symptoms as depicted in Figure 3.10. There was no significant difference between 
the groups with regard to their finishing times (p > 0.05) as depicted in Figure 3.11. 
3.5. Discussion 
This is the first study of its kind that documents symptoms as well as objective 
evidence for the presence of an infection (clinical examination, viral gargles and 
bacterial cultures from throat swabs) in ultradistance runners after an event. 
Although a mild pharyngitis was found on clinical examination in nine athletes (9%), 
there was no evidence of actual viral or bacterial infection as documented by 
negative viral gargle cultures and bacterial cultures from throat swabs. In addition, 
although there were self-reported cases of fever in previous studies (Peters, 1990; 
Peters et al, 1983; Peters et al, 1993; Peters et al, 1996), none of the athletes 
presenting with symptoms demonstrated an elevated temperature or resting pulse 
rate in this study. It has always been postulated that runners presenting with 
symptoms after an endurance event suffer from infections, but this study fails to 
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support this hypothesis. 
The incidence of upper respiratory tract symptoms in the time period O to 3 days 
after an ultradistance event was significantly decreased after the administration of a 
topical antibacterial/anti-inflammatory agent (fusafungine). 
Fusafungine effectively reduced the incidence upper respiratory tract symptoms 
from 40% in the placebo group to 17% in the active group in the three days after the 
event. This occurred despite the fact that no evidence of bacterial or viral infection 
could be documented. It therefore appears that the mechanism by which 
fusafungine reduced the incidence of upper respiratory tract symptoms is by its local 
anti-inflammatory action on the nasal and pharyngeal mucosa alone. 
Furthermore, the beneficial effect of fusafungine is only evident in the first three 
days after the ultradistance event. This implies that the inflammatory response was 
maximal in this time period which would be consistent if the "injury" occurred on the 
day of the race, resulting in a maximal acute inflammatory response in days 0-3. 
The pathological mechanism responsible for the production of upper respiratory 
tract symptoms after ultradistance events is not clear, but may be local 
inflammation, which is maximal in the first three days after the event. There is no 
evidence that the inflammatory response is due to infection, and may be due to 
mechanical irritation from dust or other particles, rapid air movement or drying of the 
respiratory mucosa by obligatory mouth breathing during the event. 
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In this study the incidence of upper respiratory tract symptoms in the placebo group 
in the first few days after an ultramarathon event was 40%. This is similar to the 
incidence of post-race symptoms in previous studies (Peters, 1990; Peters et al, 
1983; Peters et al, 1993; Peters et al, 1996). As documented in other studies 
(Peters, 1990; Peters et al, 1993; Peters et al, 1996), nasal symptoms (blocked 
nose and runny nose) were most common, followed by a sore throat. In contrast, in 
their previous study at the Two Oceans Marathon (Peters et al, 1983), Peters and 
Bateman found that sore throat was the most prevalent symptom, followed by nasal 
symptoms. In all these studies (Peters, 1990; Peters et al, 1983; Peters et al, 1993; 
Peters et al, 1996) the authors did not differentiate between blocked or runny nose 
when documenting nasal symptoms. 
High weekly mileage was associated with an increased risk for the development of 
upper respiratory tract symptoms. This is consistent with previous findings (Heath et 
al, 1991; Nieman et al, 1990; Peters et al 1983; Peters et al, 1993). In contrast, two 
other studies (Peters, 1990; Peters et al, 1996) found that athletes who did the least 
training had the highest incidence of post-race upper respiratory tract symptoms. 
Upper respiratory tract infections, however, remain a real dilemma for ultradistance 
athletes. Until further research provides clarity regarding the relationship between 
upper respiratory tract symptoms and true infection in these athletes the following 
preventative measures are advised. Athletes should minimise exposure to 
pathogens by avoiding contact with infected individuals, especially children 
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(Shephard et al, 1993). Since viruses are often transmitted by hand contact, the 
hands should be washed regularly and any rubbing of eyes or nose should be 
avoided (Shephard et al, 1993). For those athletes engaged in high intensity 
training further preventative measures include spacing vigorous workouts and race 
events as far apart as possible, eating a well balanced diet, keeping life stresses to 
a minimum, avoiding over-training and obtaining adequate sleep (Heath et al, 1992). 
Vitamin supplementation (especially Vitamin C) may also be beneficial (Peters et al, 
1993). Athletes may be innoculated against viruses endemic to the area where they 
may compete (Shephard et al, 1993). Muscular immunoglobulin injections may 
reduce the incidence, duration and severity of upper respiratory tract illness in 
athletes (Nieman et al, 1991 ). 
Athletes who develop symptoms of upper respiratory tract infection are advised to 
follow a suggested "neck check" (Eichner, 1993) when deciding to exercise while 
infected. If all the symptoms are" above the neck" (runny or stuffy nose, scratchy 
throat), the athlete could begin their exercise routine at below normal intensity for 
ten minutes. If the activity made them feel worse, they should stop exercising, but if 
they feel better, they should continue with training. However, if any symptoms were 
"below the neck" (muscle aches, cough, vomiting, diarrhoea or fever) training should 
be discontinued (Eichner, 1993). 
Finally, ultradistance runners who regularly suffer from upper respiratory tract 
symptoms post exercise can be advised to use a local anti-inflammatory agents 
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such as fusafungine to decrease the risk of developing symptoms. The duration of 
treatment should be limited to 3-5 days post event. 
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Table 3.1: Physical characteristics, training history and running 
intensity in the active and placebo groups (values are 
mean ± standard deviation). 
69~(year~L __ _ 
He_i_gb_tJ~m) 
WeiglJ_t_(~g) 
Trai11Lng_volumeJkQ1/week} __ 
Jraining s_p~~d (min/1(111) 
§_61<m fin_i§__hir,g time (hJ§) ___ _ 
No significant difference between groups 
~~tive (ri=42_L 
39 ± 8 
177 ± 8 
76 ± 10 
66 ± 19 
4.96 ± 0.40 
-- ---- . 
5.1 ± 0.6 
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-~~ac~tJo {n=4.§L --~- . 
38 ± 9 
178 ± 8 
72 ± 8 
68 ± 22 
4.81 ± 0.5 
5.1 ± 0.6 
Table 3.2: Dietary intake of nutrients in the active and placebo 
groups (values are mean ± standard deviation). 
_Energy (kJ) 
Fat (g) 
fEQ1E)_iri (g). 
Carbohydrate {9) .. 
\/l_t_amin A (iu) ... - _ 
Beta Carotene (lllg) _ 
Yitamin c (mg) 
y~aminE{iu) 
10014 ± 2470 
97 ± 37 
91 ± 18 
262 ± 68 
1327 ± 726 
- ---- -- -- - - - --~ - -
8±4 
616 ± 599 
25 ± 21 
No significant difference between groups 
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15349 ± 20758 
110 ± 36 
102 ± 36 
305 ± 98 
2072 ± 2237 
10 ± 7 
702 ± 611 
28 ± 22 
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Figure 3.2: Incidence of blocked nose in ultradistance runners 
(n = 90). No significant difference between groups. 
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Figure 3.3: Incidence of runny nose in ultradistance runners 
(n = 90). No significant difference between groups. 
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Figure 3.4: Incidence of a sore throat in ultradistance runners 
(n = 90). No significant difference between groups. 
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Figure 3.5: Incidence of a cough in ultradistance runners (n = 90). 
No significant difference between groups. 
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Figure 3.6: Incidence of nasal symptoms in ultradistance runners 
(n = 90). No significant difference between groups 
(* p = 0.085). 
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Figure 3.7: Incidence of upper respiratory tract symptoms in 
ultradistance runners (n = 90). Significant difference 
between groups (* p = 0.025). 
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Figure 3.8: Incidence of all respiratory tract symptoms in 
ultradistance runners (n = 90). Significant difference 
between groups (* p = 0.028). 
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Figure 3.9: Incidence of all post race respiratory tract symptoms in 
ultradistance runners fron Day O to 9 (n = 90). 
No significant difference between groups. 
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Figure 3.10: The training volume in asymptomatic runners (n = 48) 
and symptomatic runners (n = 48). Significant 
difference between groups(* p = 0.0156). 
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Figure 3.11 :The finishing times in asymptomatic runners (n = 48) 
and symptomatic runners (n = 46). No significant 
differences between groups (p > 0.05). 
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Figure 3.12: Incidence of all post race upper respiratory tract 
symptoms in ultradistance runners from Day O to 9 
(n = 90). No significant difference between groups. 
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No significant difference between groups. 
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difference between groups. 
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Incidence of post race sore throat in ultradistance 
runners from Day O to 9 (n = 90). 
No significant difference between groups. 
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Incidence of post race runny nose in ultradistance 
runners from Day O to 9 (n = 90). 
No significant difference between groups. 
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No significant difference between groups. 
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Chapter 4 
Summary 
Epidemiological data shows that athletes who engage in ultradistance running are at 
increased risk for developing symptoms of upper respiratory tract infection during 
times of intense training and the two week post-race period (Nieman et al, 1990; 
Peters, 1990; Peters et al, 1983; Peters et al, 1993; Peters et al, 1996). In contrast, 
athletes who engage in moderate physical activity report less symptoms and may 
show enhanced resistance to infection (Nieman, 1994; Nieman et al, 1993; Nieman 
et al, 1990). Although numerous immunological changes may be documented after 
intense or prolonged exercise, most are transient and their exact role in producing 
susceptibility to infection remains elusive (Simon, 1987). 
Upper respiratory tract infections however, remain a real dilemma for athletes. Even 
a minor illness limits training and this may impair performance in an upcoming 
event. In addition, the dangers of exercising while infected with a virus are well 
known. As these infections are mainly viral, treatment is symptomatic and 
prevention would therefore be more desirable (Heath et al, 1992; Shephard et al, 
1993). 
One of the major limitations of most previous studies to determine the relationship 
between upper respiratory tract infection and exercise is that they relied on self 
reported symptoms by the athlete. A true measure of outcome is impossible to 
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ascertain without a clinical examination and laboratory documentation of infection. 
In this study there was no evidence of viral or bacterial infection in any of the 
subjects who presented with symptoms, as documented by negative viral gargle 
cultures and bacterial cultures from throat swabs. In addition, the administration of a 
topical anti-inflammatory/anti-bacterial agent (fusafungine) effectively reduced the 
incidence of upper respiratory tract symptoms from 40% to 17% in the first few days 
after an ultradistance event. These findings imply that in many athletes the 
symptoms of upper respiratory tract infection that are reported may in fact be due to 
local inflammation and not actual infection. This has important implications for 
further participation in running as well as the necessity for treatment. 
Further research should therefore be directed at documenting an increase in true 
infection in ultradistance runners as opposed to self reported symptoms. In addition, 
it may be useful to investigate the benefit of using a pure topical anti-inflammatory 
agent such as an inhaled local corticosteroid. 
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APPENDIX 1 
CASE REPORT FORM 
Title : 
The effect of fusafungine (Locabiotal ®) on 
the incidence of upper respiratory tract 
infections in ultra distance runners 
Patient N° ODD 
Patient Surname I l 
Patient Initials I I 
SECTION A - Pre Race Assessment 
1. Personal Details 
Surname 
First Names 
Age 
Date of Birth 
Weight 
Height 
Occupation 
Work Tel N° 
Home Tel N° 
Postal Address 
2. General Medical History 
A. Family History 
I dd I 
I I 
I I 
Patient Number 
I mm I I \A/ 
kg 
cm 
((ld(' 
Have any of your relatives ever had the following ? Please tick yes / no and list your relationship of that person to you 
Description yes no Relationship 
High Blood Pressure 
Cancer 
Epilepsy 
Psychiatric Abnormalities 
Asthma 
Tuberculosis 
Diabetes 
Kidney Disease 
\, . 
ii 
I I I 
Patient Initials I I I I I I I I I Patient Number I I I I I 
2. General Medical History 
--
B. Personal Medical History 
- --~-- - - - ----- --- ---------
Have you had any of the following (please tick the appropriate block) 
Description yes no Description yes no 
Surgery Genetic Disorders 
Head Injury with unconsciousness Sugar in urine 
Kidney stones Epilepsy 
Ear, nose & throat disorders Weakness / Paralysis 
Hay fever Hernia 
Asthma Disease of joints 
Tuberculosis Lower back pain 
Rheumatic fever Cancer 
Heart murmer Allergy 
High blood pressure Skeletal pain / cramps 
Chest pain at rest Blood in the stool 
Chest pain during exercise Stomach or intestinal disorder 
Recurrent diarrhoea Jaundice or Hepatitis 
Urinary tract infection 
1. Do you smoke ? I yes I I no I 
2. Approximately how many respiratory tract infections have you had on average over the past five (5) years (per year) ? 
I none I ~ 0 0 ~ 8 
3. How many hours per night do you sleep on average ? B ~ §] §] B 
4. Do you live I alone I I with friends I I family I I family &. children I 
5. Have you had any extraordinary social / emotional stress recently ? 
(e.g. death/ illness in family, marital disharmony, work related) ? I yes I I no I 
6. How much alcohol do you drink (tots, glasses of wine/ beers) per week 0 B ~ §] B 
' . 
Patient Initials Patient Number 
2. General Medical History 
C. Training History 
How many years have you participated in endurance running 7 
2 In the last six (6) months during training, what has been : 
i) Your km / week done on average 
ii) Average speed in mins / km 
4 During the last month has your training distance 7 
5 During the last month has your training intensity 7 
6 Do you participate in other sport 7 
D. Nutritional and Supplements 
Are you taking dietary supplements / vitamins ? 
2 What is its/ their name (s) 
3 What dosage are you taking (of each if applicable) ? 
4 For how long have you been taking it / them ? 
5 Do you carbo - load before the race 
< 40 
>5 
1 40 - 60 1 
1 4 - s 
remained the same 
remained the same 
yes no 
yes no 
yes no 
1 60 - 80 1 
3 - 4 
increased 
increased 
iv 
> 80 
<3 
decreased 
decreased 
V 
Patient Initials Patient Number I I I 
SECTION A - Pre Race Assessment 
2. General Medical History 
E. Physical Examination 
Pulse rate (beats / min) < 60 
Temperature 
Description yes no Specify 
Lymph nodes in neck 
Pharynx inflamed 
Nasal Mucosa inflamed 
Ear drums inflamed 
Left lung apex clear 
Left lung base clear 
Right lung apex clear 
Right lung base clear 
Heart sounds normal 
Heart murmers 
Included in Trial Yes No 
Instructed on use of Locabiotal Yes No 
Locabiotal dispensed Yes No 
Patient diary A given Yes No 
VI 
Patient Initials I I Patient Number I I 
SECTION B - Day 6 Assessment 
Day 6 Assessment 
1. Patient Diary A received GJ [;] 
2. Symptoms of URTI present GJ [;] 
3 If symptoms present - physical examination 
a. Pulse rate (beats/ min) ~ ~ ~ ~ 
b Temperature ~ ~ ~ ~ 
Description yes no Specify 
Lymph nodes in neck 
Pharynx inflamed 
Ear drums inflamed 
Ear drums inflamed 
Lett lung apex clear 
Lett lung base clear 
Right lung apex clear 
Right lung base clear 
Heart sounds normal 
Heart murmers 
Throat swabs done for bacterial culture 
Cargle done for viral culture 
Throat swab positive 
Gargle positive 
vii 
Patient In it i a Is\.______.___\ ____._____.___...._j _...._I _...._j _...._____, Patient Number I I I I 
SECTION C - Day 12 Assessment 
Day 12 Assessment 
1 . Patient Diary B received [EJ GJ 
2. Symptoms of URTI present [EJ GJ 
3. If symptoms present - physical examination 
a. Pulse rate (beats/ min) B ~ ~ ~ 
b. Temperature ~ ~ ~ ~ 
Description yes no Specify 
Lymph nodes in neck 
Pharynx inflamed 
Ear drums inflamed 
Lett lung apex clear 
Lett lung base clear 
Right lung apex clear 
Right lung base clear 
Heart sounds normal 
Heart murmers 
Throat swabs done for bacterial culture 
Cargle done for viral culture 
Throat swab positive 
Gargle positive 
APPENDIX 2 VIII 
Patient Initials Patient Number I I I 
PATIENT DIARY A 
1. What was your time for the race hours minutes 
2 Development of symptoms 
Please tick the appropriate block indicating the day of onset and days of duration of any symptoms experienced 
I Description Thu Fri Sat Sun Mon Tue 
4.4.96 5.4.96 6.4.96 7.4.96 8.4.96 9.4.96 
Sore throat 
Blocked nose 
Running nose 
Cough 
Fever 
General body aches 
Tiredness / fatigue 
No symptoms 
3. Locabiotal administration Chart 
Day & Date Morning LunJ~time Afternoon Evening 
Thursday 4.4.96 
Friday 5.4.96 
Saturday 6.4.96 
Sunday 7.4.96 
Monday 8.4.96 
Tuesday 9.4.96 
Please be honest - leave out any dosage not taken 
4. Did you experience any side effect from the Locabiotal ? yes no 
Specify 
Patient Initials Patient Number 
P-ATIENT DIARY B 
1. Development of Symptoms 
Please tick the appropriate block indicating the day of onset and days of duration of any symptoms experienced 
Description 
Sore throat 
Blocked nose 
Running nose 
Cough 
Fever 
General body aches 
Tiredness / fatigue 
No symptoms 
Thu 
10.4.96 
3. Locabiotal administration Chart 
Day & Date Morning 
Thursday 10.4.96 
Friday 11.4.96 
Saturday 12.4.96 
Sunday 13.4.96 
Monday 14.4.96 
Tuesday 15.4.96 
Please be honest - leave out any dosage not taken 
Fri 
11.4.96 
Lunchtime 
II 
4. Did you experience any side effect from the Locabiotal ? 
Specify 
Sat 
12.4.96 
yes 
Sun 
13.4.96 
Afternoon 
no 
Mon 
14.4.96 
ix 
I I 
Tue 
15.4.96 
Evening 
X 
APPENDIX 3 
APRIL 1996 
DIETARY ANALYSIS 
PRELIMINARY DATA FOR DR M. KIESSIG -SPORTS SCIENCE INSTITUTE OF S.A. 
NAME: DATE: 
AGE: WEIGHT: HEIGHT: 
TRAINING LOAD: daily weekly 
In order to obtain useful and accurate dietary information for the purpose of this study, 
please record all the foods you eat over a 3 day period as you eat them! It is very 
important that you try and document the quantities of each food item or drink in the 
dish or meal. Where possible please use standard serve sizes such as cups, 
tablespoons, teaspoons etc. For meat and other protein products describe the cooked 
prece(s) in terms of number of matchboxes or actual weight. 
DAY1 
FOODS 
EATEN 
Morning beverage 
fruiUveg 
bread/cereal 
milk/yoghurt 
butter/marg/oil 
* rotein 
Mid-morning beverage 
fruiUveg 
bread/cereal 
milk/yoghurt 
butter/marg/oil 
*protein 
Lunch beverage 
fruiUveg 
bread/cereal 
milk/yoghurt 
butter/marg/oil 
*protein 
Mid-afternoon beverage 
fruiUveg 
bread/cereal 
milk/yoghurt 
butter/marg/oil 
*protein 
Evening beverage 
fruiUveg 
bread/cereal 
milk/yoghurt 
butter/marg/oil 
QUANTITY PREPARATION/ 
ADDITIONS/ 
SAUCE 
_______ ____J)f{)tein ---------------------------------
Late-evening beverage 
fruiUveg 
bread/cereal 
milk/yoghurt 
butter/marg/oil 
• rotein 
WHAT NUTRITIONAL SUPPLEMENTS DID YOU TAKE TODAY? 
XI 
DAY2 
FOODS 
EATEN 
Morning beverage 
fruit/veg 
bread/cereal 
milk/yoghurt 
butter/marg/oil 
• rotein 
Mid-morning beverage 
fruit/veg 
bread/cereal 
milk/yoghurt 
butter/marg/oil 
* rotein 
Lunch beverage 
fruit/veg 
bread/cereal 
milk/yoghurt 
butter/marg/oil 
• rotein 
Mid-afternoon beverage 
fruit/veg 
bread/cereal 
milk/yoghurt 
butter/marg/oil 
_____ *protein 
~~~- -~~
~~~ 
Evening beverage 
fruit/veg 
bread/cereal 
milk/yoghurt 
butter/marg/oil 
*protein 
Late-evening beverage 
fruit/veg 
bread/cereal 
milk/yoghurt 
butter/marg/oil 
* rotein 
QUANTITY PREPARATION/ 
ADDITIONS/ 
SAi ICS:: 
WHAT NUTRITIONAL SUPPLEMENTS DID YOU TAKE TODAY? 
XII 
DAY3 
FOODS 
EATEN 
Moming beverage 
fruiUveg 
bread/cereal 
:milk/yoghurt 
ibutter/marg/oil 
'* rotein 
Mid-moming beverage 
fruiUveg 
:bread/cereal 
milk/yoghurt 
. butter/marg/oil 
'* rotein 
Lunch beverage 
fruiUveg 
bread/cereal 
milk/yoghurt 
butter/marg/oil 
*protein 
Mid-afternoon beverage 
fruiUveg 
bread/cereal 
milk/yoghurt 
butter/marg/oil 
*protein -----~-~------
-~~~-
Evening beverage 
fruit/veg 
bread/cereal 
milk/yoghurt 
butter/marg/oil 
*protein 
Late-evening ·beverage 
fruit/veg 
bread/cereal 
milk/yoghurt 
butter/marg/oil 
* rotein 
QUANTITY PREPARATION/ 
ADDITIONS/ 
SAUCE 
WHAT NUTRITIONAL SUPPLEMENTS DID YOU TAKE TODAY? 
WHAT ADDITIONAL SUPPLEMENTS ARE YOU TAKING? 
xiii 
